Mark J. Levis, Mehdi Hamadani, Brent R. Logan, Richard J. Jones, Anurag K. Singh, Mark R. Litzow, John R. Wingard, Esperanza B. Papadopoulos, Alexander E. Perl, Robert J. Soiffer, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey L. Uy, Edmund K. Waller, Sumithira Vasu, Melhem Solh, Asmita Mishra, Lori S. Muffly, Hee-Je Kim, Matthias Stelljes, Yuho Najima, Masahiro Onozawa, Kirsty Thomson, Arnon Nagler, Andrew H. Wei, Guido Marcucci, Caroline Chen, Nahla Hasabou, Matt Rosales, Jason Hill, Stanley C. Gill, Rishita Nuthethi, Denise King, Adam Mendizabal, Steven M. Devine, Mary M. Horowitz, Yi-Bin Chen. "Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML." Blood, 2025. doi:10.1182/blood.2024025154